Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have synthesized radiolabeled compounds acting as GABA(A) receptor subunit α2β2γ1 (GABRA2) positive allosteric modulators acting as positron-emission tomography (PET) and autoradiography imaging agents reported to be useful for the diagnosis of neurological disorders.

Allianthera (Suzhou) Biopharmaceutical Co. Ltd. has disclosed EGFR (HER1; erbB1) inhibitors reported to be useful for the treatment of cancer.

Shanghai Institute of Organic Chemistry has described oleanamide derivatives acting as Kelch-like ECH-associated protein 1 (KEAP1)/nuclear factor erythroid 2-related factor 2 (NFE2-related factor 2; NFE2L2; NRF2)/antioxidant response element (ARE) pathway activators reported to be useful for the treatment of amyotrophic lateral sclerosis, diabetes, multiple sclerosis, renal disorders, Huntington's disease, Parkinson's disease, autoimmune disease and Alzheimer's disease, among others.

Université de Genève has divulged adenosine A2A receptor (ADORA2A) antagonists reported to be useful for the treatment of cancer.

DE Shaw Research LLC has identified transient receptor potential cation channel subfamily A member 1 (TRPA1) antagonists reported to be useful for the treatment of pain, fibrosis, autoimmune disease, neurological, dermatological, cardiovascular, respiratory and gastrointestinal disorders, among others.

Researchers from Centre National de la Recherche Scientifique, Inserm, Université Claude Bernard and Université Jean Monnet have synthesized peptides acting as amyloid-β (Aβ) protein aggregation inhibitors reported to be useful for the treatment of amyotrophic lateral sclerosis, cerebral amyloid angiopathy, Down syndrome, Parkinson's disease, Alzheimer's disease and motor neuron disease.

Korea Research Institute of Chemical Technology has disclosed mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) and mitogen-activated protein kinase kinase kinase 11 (MAP3K11; MLK3) inhibitors reported to be useful for the treatment of Parkinson's disease, viral infection, cancer, tuberculosis and non-alcoholic steatohepatitis.

Esperion Therapeutics Inc. has described ATP citrate lyase (ACLY) inhibitors reported to be useful for the treatment of cancer and more.

Novartis AG has divulged pyrazolopyrimidine derivatives acting as methylcytosine dioxygenase TET2 inhibitors and thus reported to be useful for the treatment of cancer.

Merck Sharp & Dohme LLC has identified orexin OX2 receptor agonists reported to be useful for the treatment of hypersomnia and narcolepsy.